Galaxy Therapeutics

🌍 SEAL IT IDE Trial update 🌍 Galaxy Therapeutics is pleased to announce the enrollment of two more patients in the SEAL IT IDE trial at Cooper University Hospital, under the expert guidance of Dr. Daniel Tonetti and his team. Each enrollment represents a collective effort and a step forward in understanding aneurysm treatment. We’re proud to collaborate with top institutions and experts, continuously expanding our insights and strengthening our path in this critical research journey. Stay tuned as we continue to share updates from sites across the country! #GalaxyTherapeutics #SEALITTrial #Neurointervention 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.    𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

🌍 SEAL ME Update – 5th Enrollment in Europe! 🌍 Galaxy Therapeutics is thrilled to share that our SEAL ME Global registry has reached another milestone, with the enrollment of our 5th patient at Hospital Vall d’Hebron in Barcelona! Our deepest appreciation goes to Dr. Alejandro Tomasello Weitz, Dr.David Hernández Morales, and their dedicated team for their tremendous work. Stay tuned for more updates as we continue this journey together, partnering with expert teams around the globe! #GalaxyTherapeutics #Neurointervention #SEALME 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.    𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

🌍 Progress Update: SEAL IT IDE Trial Enrollment Milestone 🌍 Galaxy Therapeutics is excited to share that 9 additional patients have been recruited in the SEAL IT IDE trial! 🏥 Enrollment Highlights: • University of Utah – 3 patients • Rockford Memorial Hospital – 1 patient • JFK Medical Center, New Jersey – 1 patient • Cooper University Hospital – 1 patient • Wake Forest Baptist Health – 1 patient • University of Chicago – 1 patient A huge thank you to each of these centers and their remarkable teams for their ongoing commitment and collaboration. Your efforts are vital to the continued success of this trial! 📢 Follow us to stay updated on the SEAL IT IDE trial’s progress and for more insights into our journey toward pioneering advancements in neurointervention. #ClinicalTrials #SEALIT #GalaxyTherapeutics 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.    𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

We are thrilled to announce that Dr. James Caldwell and his team at Auckland City Hospital, New Zealand, have successfully enrolled another patient in our Global SEAL Me registry! 🎉 At Galaxy Therapeutics, we continue to push the boundaries of innovation to improve patient outcomes worldwide. Stay tuned as we advance in our mission to revolutionize aneurysm treatment. #MedicalInnovation #BrainAneurysm #SEALDevice #Neurointervention #Neurosurgery #GalaxyTherapeutics #ClinicalTrials #InnovationInHealthTech #SEALMe 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.    𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥. 

The Galaxy Therapeutics team is pleased to share progress in the SEAL IT IDE trial with four cases successfully recruited in the US! 3 cases at JFK Medical Center by Dr. Jankowitz 1 case at Rutgers Health by Dr. Priyank Khandelwal A big thank you to the teams for their commitment to advancing research in this critical area. Stay tuned for more updates as we continue our efforts in this important trial. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

Allison Twigg has joined Galaxy as a Clinical Education and Training Specialist. Allison is a nurse with focus on Neuroendovascular procedures. She brings with her deep experience and passion for Neuroendovascular care.

Galaxy is excited to announce that Chris Pierzchalski has joined the team as a consultant. Chris will serves as the Director of Clinical Affairs. He brings in over a decade of experience in Neurointerventional space. Welcome to the Galaxy family Chris!

Galaxy welcomes Britt Demoulin to the family. Britt will serve as a Clinical Education and Training Specialist. He brings in a wealth of knowledge as a Neurointerventional Technologist.

🚀 Exciting news from Galaxy Therapeutics! We’ve reached an important milestone in our IDE trial by enrolling 4 new patients across two esteemed sites: 2 at Cleveland Clinic Foundation with Dr. Shazam Hussain and 2 at Wellstar Kennestone in Atlanta with Dr. Ahmad Khaldi. A heartfelt thank you to our dedicated team and proctors, Dr. Zaidi and Dr. Zaidat, for their invaluable support. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥. #Galaxy #SEAL #SEALIT

🌍 Exciting Times at WFITN 2024! 🌍 Today, our team at Galaxy Therapeutics had the incredible opportunity to participate in the WFITN 2024 conference in New York. We’re thrilled to showcase our groundbreaking intrasaccular technology, collaborating with experts and innovators in the field is vital as we strive to make a difference in patient outcomes. Check out some highlights from our activities at the conference! 📸 A huge thank you to the organizers and all the participants for fostering such inspiring discussions! We look forward to continuing to push the boundaries of what’s possible in neurointervention. #WFITN2024 #Neurointervention #MedicalDevices #Innovation #BrainHealth #GalaxyTherapeutics   𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.